Cameron Turtle compensation by year
BridgeBio Pharma Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $400,000 |
| Bonus | $210,000 |
| Stock awards | $3,940,081 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $11,400 |
| Total | $4,561,482 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BridgeBio Pharma, Inc. DEF 14A filed April 30, 2021, accession 0001193125-21-145491, and prior-year filings.
How this page was built: the BridgeBio Pharma, Inc. filed document, accession 0001193125-21-145491. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 5,249 | $373,256 | — |
| RSU | 786 | $55,892 | — |
| Option | 187,500 | — | $17.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BridgeBio Pharma, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
BridgeBio Pharma’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $10,054,909 |
| Michael Henderson | Chief Business Officer | $7,991,241 |
| Brian Stolz | Chief Operating Officer | $5,240,851 |
| Cameron Turtle · this page | Chief Strategy Officer | $4,561,482 |
| Brian Stephenson | Chief Financial Officer | $4,163,933 |
| Charles Homcy | Chairman of Pharmaceuticals | $1,855,805 |
The full BridgeBio Pharma compensation record
free company briefThis page is one person within BridgeBio Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BridgeBio Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BridgeBio Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.